Any kind of validation we can get will help immensely. A
Any kind of validation we can get will help immensely. A published paper, HIV BLA acceptance, etc.
I've always thought of CytoDyn as a good company from a bad neighborhood.
If everyone you've ever met from a certain town turned out to be a criminal, you'd be extremely leery of the next person from that town. That town is the OTC market, and CYDY has that stink all over them. It raises everyone's suspicions right away, and makes them an easy mark for BumbleFart McGee's "SCAM! Dreamcatchers! Insider Selling!" headlines.
It's why doctors and news media people can dismiss us so easily.
The funny part is that the FDA can save their reputations here too, but they are too blind to see it.
4
1
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Munters' Bold New Targets and Strategic Moves Ever feel like you're on a constant treadmill chasing numbers? Munters Group knows the feeling. Over in Stockholm, they've just laid out fresh strategies at their Capital Markets Day—not just any pie-in-the-sky type goals, but heavy hitters that are setting the tone for their future. CEO Stefan Aspman is all geared up,...
Continue Reading
Credentialing Takes Front Seat in Pharmacy World Well, hold onto your hats because the pharmacy profession is getting a major upgrade, particularly if you're an investor watching healthcare regulation. The American Association of Colleges of Pharmacy (AACP) has thrown its support behind professional credentialing for pharmacists, which is a big deal, trust me. Pharmacy...
Continue Reading
Diving Headfirst into Holiday Tech Splurging The holiday hustle is upon us, folks, and Epson's stepping up with early Black Friday deals that'll have tech heads scrambling. They’re cutting prices up to $250 on their swanky home lineup—projectors, printers, scanners, you name it. This ain't just about making someone else smile, though; it's about the sweet spot where...
Continue Reading
Revolutionizing Software Capitalization with CodeROI Forget the good old days when estimating software costs was like pinning the tail on a moving donkey. CodeROI’s latest brainchild brings a sorely needed tune-up, integrating AI development costs into software capitalization. And just in the nick of time, with FASB’s upcoming rule change looming over every tech-savvy...
Continue Reading
QFIN Executives in Legal Hot Water Qfin Holdings, Inc. (NASDAQ: QFIN) is in a tight spot as a securities class action lawsuit casts a harsh spotlight on its senior executives. The CEO and CFO, during the contested class period, are front and center in this legal tangle. Qfin's stockholders are grappling with losses, and it's all tied back to some certified SEC filings...
Continue Reading
Celebrating a Milestone: IMG's Grant Success In a world often tangled with red tape and bureaucracies, here's a clean shot of hope: IMG, aka International Medical Group, just dished out some well-earned greenbacks to groups making meaningful ripples. This year, they've upped their game by bestowing $3,500 each to Footsteps Bangladesh and Hope Ministries Uganda. Tuck those...
Continue Reading
A Fresh Approach to Storm Preparedness Natural disasters don't give you the luxury of foresight—they just roll in uninvited, leaving chaos in their wake. Now, here's a tale of someone who's taken matters into his own hands. This tinkerer from Los Angeles scratched his head long enough and came up with what he's calling the 'MENDEZ INVENTION.' A contrivance aimed at...
Continue Reading
Strengthening San Antonio's Family Law Field Brenda Marichalar is joining the ranks at Goranson Bain Ausley (GBA) with a reputation built on solid courtroom chops and a knack for making clients feel like they’re more than just case numbers. She’s landing right in San Antonio, a region that’s not just about the riverwalks and missions, but about real families...
Continue Reading
Game-Changing Results for Psoriatic Arthritis Surprising everyone this side of the stock ticker, Eli Lilly (NYSE: LLY) just announced their new data: pairing Taltz (ixekizumab) with Zepbound brought a clinical revolution for folks battling psoriatic arthritis and obesity. It's like finding gold under your mat—a combo punching PsA better than Taltz going solo. AT 52...
Continue Reading
A New Era of Voice-Driven Verification Blockchain and biometrics? Ancient history. Today, Helix drops a game-changer into the digital verification scene, raising a hefty $6.2 million in pre-seed capital. They're tackling the AI age's rampant bot issues with some slick voice-based magic. Imagine biometric-level security from a four-second challenge—not a bad little trick...
Continue Reading
Top 5 Most Recently Viewed Articles
Analyst Adjusts SolarEdge Estimates Before Key Earnings Report SolarEdge Technologies Inc (NASDAQ: SEDG) has seen a significant decline in its stock, losing over 80% of its value year to date. This downturn has raised concerns among analysts and investors alike regarding the company’s future prospects. Impact of Enphase Energy's Results Recent estimates for SolarEdge...
Continue Reading
Ascend Performance Materials Initiates Restructuring Ascend Performance Materials, a key player in the production of high-quality engineered materials, has taken significant steps to enhance its financial standing. Through a supportive partnership with its lenders, the company is undergoing a restructuring process. This strategic decision will not only strengthen the...
Continue Reading
Ozop Energy Solutions Expands Lighting Control Features Warwick, NY — Ozop Energy Solutions Inc. (OZSC) is a leader in cutting-edge lighting control technology and is making notable progress within its Automated Room Controls Inc. (ARC) division. By continuously innovating, ARC is redefining the lighting controls sector, enhancing its product offerings while adhering to...
Continue Reading
Boeing's Ambitious Financial Maneuvers Boeing Company (NYSE: BA) has recently made headlines with the announcement of two significant public offerings aimed at enhancing its financial stability. This move includes the release of 90 million shares of common stock and $5 billion in depositary shares, each reflecting a fraction of newly issued Series A Mandatory Convertible...
Continue Reading
Market Sentiment Surrounding Intel Options Recent observations indicate that investors are adopting a cautious outlook towards Intel (NASDAQ: INTC). This collective sentiment cannot be overlooked. Our analysis of options trading data revealed noteworthy movements that indicate some investors are anticipating potential changes in the stock's trajectory. Understanding the...
Continue Reading